

## **PRESS RELEASE**

### **JHL Receives Technology Based Designation from Taiwan's Ministry of Economic Affairs**

**18OCT2017**

JHL Biotech, Inc. (TPEX: 6540) is announcing that it has received a Technology Based Enterprise designation from the Industrial Development Bureau of Taiwan's Ministry of Economic Affairs.

JHL Biotech was founded with the vision of bringing high-quality, affordable biologics to all patients worldwide, including those in emerging markets with unmet medical needs. To realize this vision, JHL develops biosimilars, performs contract development and manufacturing work (CDMO) for select partners, and develops innovative biologics.

JHL's current pipeline consists of biosimilars of therapeutics for the treatment of various cancer, inflammatory, and genetic diseases: JHL1101 (rituximab for non-Hodgkin's lymphoma and rheumatoid arthritis), JHL1149 (bevacizumab for colon and other cancers), JHL1188 (trastuzumab for breast cancer), and JHL1922 (dornase alfa for cystic fibrosis). In addition, JHL's pipeline consists of four undisclosed products. Likewise, JHL has successfully completed contract programs on behalf of clients including ASLAN Pharmaceuticals, Affinita Bio, and BeiGene. JHL's contract services business generated about NTD165,609 thousand revenue in 2016.

JHL has developed an approach to therapeutics development that reduces the time and cost associated with the clinical trial and regulatory process; in addition, JHL is one of the first companies from Greater China to execute simultaneous clinical trials of a biosimilar in both Europe and China. With European clinical data and regulatory know-how and U.S. big pharma expertise, JHL is rapidly evolving into an Asian biopharma leader.

**End**

**Media Contact:**

Gregory Manker

Phone: +886-909-780-862

[gmanker@jhlbiotech.com](mailto:gmanker@jhlbiotech.com)

**About JHL Biotech**

JHL Biotech Inc. (Stock Code: 6540.TWO) is a biopharmaceutical firm founded by a group of biopharmaceutical industry veterans. JHL's investors include premier financial firms and strategic partners such as Kleiner Perkins Caufield & Byers, Biomark Capital, Milestone Capital, Sanofi, and Sequoia Capital. JHL is developing proposed biosimilars to rituximab, dornase alfa, bevacizumab, and trastuzumab. JHL1101, JHL's proposed rituximab biosimilar, is undergoing clinical trials in the European Union. In addition to biosimilars, JHL also co-develops innovative new molecules and provides contract manufacturing services to select clients. For more information, please visit [www.jhlbiotech.com](http://www.jhlbiotech.com).